Clinical Edge Journal Scan

RA raises risk for bronchial asthma and asthma-related comorbidities


 

Key clinical point: Rheumatoid arthritis (RA) was significantly associated with an increased risk for bronchial asthma, allergic rhinitis, and sinusitis, and a notable interrelation was observed between the presence of asthma and obesity in patients with RA.

Major finding: Presence of RA significantly increased the risk for asthma (odds ratio [OR] 2.32; 95% CI 1.51-3.57), allergic rhinitis (OR 1.51; 95% CI 1.08-2.10), and sinusitis (OR 1.64; 95% CI 1.08-2.50) in the whole cohort and the prevalence of obesity in patients with asthma (64.0% vs 40.2%; P = .034).

Study details: This population-based cross-sectional study included 14,272 participants, of which 334 had RA.

Disclosures: This study was supported by the National Research Foundation of Korea grant funded by the Korean Government. The authors declared no conflicts of interest.

Source: Kim JG et al. Association of rheumatoid arthritis with bronchial asthma and asthma-related comorbidities: A population-based national surveillance study. Front Med (Lausanne). 2023;10:1006290 (Mar 10). Doi: 10.3389/fmed.2023.1006290

Recommended Reading

Early treatment considerations in RA, April 2023
MDedge Rheumatology
Biosimilars and patients: Discussions should address safety, cost, and anxiety about change
MDedge Rheumatology
Registry data ‘reassure’ on biologics’ heart attack risk in rheumatoid arthritis
MDedge Rheumatology
Meta-analysis examines cancer risk concern for JAK inhibitors
MDedge Rheumatology
Patients with preexisting RA can safely initiate immune checkpoint inhibitors for cancer
MDedge Rheumatology
Discontinuing half-dose csDMARD feasible in some patients with RA in remission
MDedge Rheumatology
Tofacitinib associated with reduced risk of developing ILD in patients with RA
MDedge Rheumatology
RA onset after initiating bDMARD raises risk for severe infections
MDedge Rheumatology
Factors to guide individualized benefit-risk assessment and decision-making with tofacitinib in RA
MDedge Rheumatology
Meta-analysis reveals superior efficacy and safety outcomes with abatacept in RA
MDedge Rheumatology